Stock listing

NASDAQ:ARTV Artiva Biotherapeutics, Inc. Stock

Home listing (NASDAQ) of Artiva Biotherapeutics, Inc.

Follow Artiva Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ARTV

$3.78 USD +0.01 (+0.3%)

Close on Nov 20, 2026

Past year +19.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.77 – $3.93 USDNov 20, 2026
Volume
1.78M sharesNov 20, 2026
Market cap
$186.9M USDAt the close on Nov 20, 2026 · price × 49.43M shares outstanding
52-week range
$2.96 – $14.53 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.45M USDMedian day 473,192 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Artiva Biotherapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ARTV · Home$3.78 USD+0.01 (+0.3%)1,775,377$3.82$3.93$3.77$3.77Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARTV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.78+0.01+0.3%$3.82$3.93$3.771,775,377
$3.77-0.09-2.3%$3.875$3.94$3.75972,615
$3.86-0.10-2.5%$3.95$3.99$3.811,403,652
$3.96-0.05-1.2%$3.98$4.065$3.9251,311,979
$4.01+0.05+1.3%$4.00$4.035$3.905868,508
$3.96-0.11-2.7%$4.05$4.095$3.931,436,864
$4.07+0.01+0.2%$4.10$4.13$4.045870,853
$4.06-0.16-3.8%$4.19$4.22$4.04925,853
$4.22+0.07+1.7%$4.20$4.255$4.14939,951
$4.15+0.02+0.5%$4.16$4.24$4.13908,723
$4.13-0.09-2.1%$4.19$4.22$4.07976,833
$4.22+0.02+0.5%$4.25$4.28$4.16754,021
$4.20+0.01+0.2%$4.24$4.25$4.155623,313
$4.190.000.0%$4.21$4.24$4.14938,152
$4.19-0.04-0.9%$4.20$4.26$4.101,966,165
$4.23-0.045-1.1%$4.22$4.27$4.1531,890,513
$4.275+0.005+0.1%$4.35$4.39$4.222,884,135
$4.27-1.89-30.7%$4.25$4.45$4.008,673,746
$6.16+0.01+0.2%$6.15$6.25$5.95487,078
$6.15-0.05-0.8%$6.16$6.17$5.95315,489
$6.20-0.29-4.5%$6.38$6.65$6.16393,902
$6.49-0.07-1.1%$6.60$6.74$6.44363,943
$6.56+0.67+11.4%$5.89$6.65$5.86449,925
$5.89+0.04+0.7%$5.97$6.20$5.76536,922
$5.85-0.21-3.5%$6.08$6.10$5.82573,256
$6.06+0.15+2.5%$5.93$6.16$5.85478,246
$5.91-0.38-6.0%$6.21$6.25$5.88707,557
$6.29-0.48-7.1%$6.74$6.74$6.236526,968
$6.77-0.17-2.4%$6.92$6.943$6.73248,580
$6.94+0.14+2.1%$6.84$7.135$6.77275,938
$6.80-0.20-2.9%$6.89$6.92$6.575339,711
$7.00-0.27-3.7%$7.10$7.27$6.84324,576
$7.27+0.14+2.0%$7.12$7.38$6.92665,416
$7.13+0.30+4.4%$6.75$7.16$6.52473,192
$6.83+0.04+0.6%$6.89$7.00$6.74587,649
$6.79-0.33-4.6%$7.11$7.15$6.77444,372
$7.12+0.09+1.3%$7.10$7.40$6.96383,976
$7.03-0.02-0.3%$7.06$7.18$6.92450,565
$7.05+0.06+0.9%$6.91$7.185$6.75437,532
$6.99-0.50-6.7%$7.48$7.49$6.90507,137
$7.49-0.23-3.0%$7.62$7.71$7.22511,722
$7.72-0.37-4.6%$7.99$8.20$7.52407,794
$8.09+0.26+3.3%$7.87$8.39$7.855437,976
$7.83-0.78-9.1%$8.63$8.64$7.78629,415
$8.61+0.17+2.0%$8.45$8.75$8.402,208,401
$8.44-0.16-1.9%$8.66$8.72$8.35456,517
$8.60-0.31-3.5%$8.89$9.03$8.485516,987
$8.91-1.23-12.1%$10.05$10.05$8.84584,582
$10.14-0.08-0.8%$10.21$10.55$10.13243,866
$10.22-0.20-1.9%$10.49$10.61$10.10228,437
$10.42-0.37-3.4%$10.70$10.93$10.36449,476
$10.79-0.09-0.8%$10.78$11.15$10.73325,338
$10.88-0.31-2.8%$10.83$11.16$10.70211,697
$11.19+0.065+0.6%$11.02$11.34$10.94168,592
$11.13-0.185-1.6%$11.34$11.35$10.98365,624
$11.31+0.03+0.3%$11.26$11.51$11.05306,518
$11.28-0.02-0.2%$11.00$11.36$10.88268,855
$11.30+0.21+1.9%$11.01$11.35$10.88249,844
$11.09-0.85-7.1%$11.78$11.80$11.00223,493
$11.94+0.17+1.4%$11.72$12.08$11.56218,273
$11.770.000.0%$11.75$11.93$11.60262,556
$11.77+0.25+2.2%$11.60$11.91$11.53266,361
$11.52+0.59+5.4%$10.83$11.70$10.49307,236
$10.93-0.21-1.9%$11.26$11.60$10.76199,424
$11.14-0.56-4.8%$11.50$11.58$10.93319,084
Ticker
NASDAQ:ARTV
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Artiva Biotherapeutics, Inc. news

Artiva Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 39 in all · newest Oct 27, 2026 · oldest 2024
Decks
7 decks · latest Sep 23, 2026

Where Artiva Biotherapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARTV · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ARTVBOATSUnited StatesUSD

Valuation

Price/book 0.6× against a median of 2.5×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$123.1M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Artiva Biotherapeutics, Inc. · NASDAQ:ARTVUS$186.9M−US$123.1Mn/an/an/a0.6×n/a0.0×1.34
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
SillaJen, Inc. · KRX:215600US$193.5MUS$141.7Mn/a17.6×n/a2.6×−223.8%0.0×n/a
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
Cartesian Therapeutics, Inc. · NASDAQ:RNACUS$187.3MUS$114.5Mn/a112×n/an/an/an/a1.23
Inventage Lab, Inc. · KRX:389470US$185.9MUS$113.3Mn/a61.3×n/a2.8×−127.0%0.2×n/a
Inhibikase Therapeutics, Inc. · NASDAQ:IKTUS$185.2M−US$8.17Mn/an/an/a1.0×n/a0.0×1.50
Antengene Corporation Limited · HKEX:6996US$183.1MUS$107.1Mn/a6.8×n/a1.3×−227.0%0.3×n/a
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Median of the othersUS$185.5MUS$113.9M17.6×2.5×−222.8%0.0×1.29

Forecasts

2 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
20.75 USD · Analysts' mean
EPS, year to Dec 2026
-2.64 · 5 analysts

Team and board

Officers

OfficerRole
Fred AslanChief Executive Officer
Thad HustonChief Financial Officer and Award of Inducement Grant
Jennifer BushChief Operating Officer
Adria CarboVP, Business Development
Benjamin DeweesSVP, Regulatory Affairs
Cliff WallaceVP, Quality
David MoriartySVP, Clinical Operations
Feng XuSVP, Biometrics
Heather RaymonSVP, Research & Early Development
Ilias AlevizosVP, Clinical Development
John O’NeilVP, Finance
Larry KovalickVP, Medical Affairs
Nicholas VeomettVP, Corporate Development
Sara MillsVice President, AlloNK® Program Leader
Christopher HoranChief Technical Operations Officer
Subhashis BanerjeeChief Medical Officer

Board

DirectorRole
Diego MirallesDirector
Elaine SorgDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−3.8%
Q2 2026Aug 6, 2026 · After close−2.7%
Q1 2026May 8, 2026 · Before open−13.0%
Q4 2025Mar 30, 2026+28.5%
Q3 2025Nov 12, 2025 · Before open+10.9%
Q2 2025Aug 7, 2025 · Before open−8.0%
Q1 2025May 8, 2025 · Before open+3.8%
Q4 2024Mar 24, 2025−6.6%
Q3 2024Nov 12, 2024 · After close−10.5%
Q2 2024Aug 29, 2024 · After close+2.1%
All 11 quarters
QuarterResultsShare move
Q1 2024May 29, 2024

Open Events

Decks

DeckKindSlidesDate
17th International Symposium on Sjögren's Disease 2026Conference18 slidesSep 23, 2026
Post-EULAR Virtual Webcast (June 2026)Conference37 slidesJun 8, 2026
EULAR 2026Conference15 slidesJun 6, 2026
EULAR 2026Conference15 slidesJun 3, 2026
Investor Presentation (May 2026)Investor deck33 slidesMay 2026
Corporate Update (November 2025)Corporate update30 slidesNov 12, 2025
Investor Presentation (August 2024)Investor deck21 slidesAugust 2024

Open Decks

IPO

Priced at US$12.00 a share on Jul 18, 2024.

Price
US$12.00 a share
Shares offered
13,920,000 shares of common stock
Offering size
US$167 million
Underwriters' option
Up to 2,088,000 more shares
Underwriters
Jefferies, TD Cowen, Cantor, Wedbush PacGrow, Needham & Company · In the order on the cover
Shares delivered
On or about Jul 22, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceMay 3, 2024
Filed publiclyJun 28, 2024
Amended onceJul 15, 2024
Shares registered with an exchangeJul 16, 2024
Declared effective by the SECJul 18, 2024
Final prospectus, with the priceJul 22, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jul 22, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue0251.0K33.5M4.93M2.00M0
Cost of revenue2.60M
Gross profit-2.60M251.0K33.5M4.93M2.00M
Research and development69.5M50.3M50.3M44.0M42.4M13.8M
Selling, general and administrative20.3M17.2M13.9M20.8M12.9M4.43M
Operating income-89.8M-67.3M-30.7M-59.8M-53.3M-18.3M
Depreciation and amortization2.60M2.43M2.27M1.16M248.0K73.0K
EBITDA-87.2M-64.9M-28.4M-58.7M-53.0M-18.2M
Interest expense0199.0K
Income before tax83.9M-65.4M-28.6M-58.3M-71.8M-18.0M
Income tax0072.0K53.0K-18.6M676.0K
Net income-83.9M-65.4M-28.7M-58.4M-71.8M-18.0M
Earnings per share, basic-3.43-5.81-35.78-3.32-4.08-1.02
Earnings per share, diluted-3.43-5.81-35.78

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents26.7M40.2M53.5M102.5M160.9M25.4M1.87M
Short-term investments81.3M145.2M23.5M0
Receivables767.0K01.03M525.0K468.0K0
Current assets112.7M188.6M79.8M104.7M162.3M26.1M1.96M
Property, plant and equipment6.62M6.37M8.10M
Total assets130.9M209.6M105.1M133.1M169.9M29.2M4.84M
Accounts payable355.0K1.12M614.0K1.10M1.44M2.15M258.0K
Current liabilities13.1M12.3M12.2M25.6M19.3M5.76M942.0K
Long-term debt5.64M
Total debt10.9M14.4M16.9M19.4M1.74M2.12M7.82M
Total liabilities21.0M22.9M50.7M273.8M258.8M50.8M8.80M
Shareholders' equity110.0M186.6M-162.0M-140.7M-88.9M-21.6M-3.96M
Shares outstanding49.4M49.4M24.7M17.6M17.6M17.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-76.8M-55.0M-47.4M-50.8M-15.3M-13.5M
Capital spending-2.59M-642.0K-3.26M-6.30M-1.72M-284.0K
Free cash flow-79.3M-55.7M-50.7M-57.1M-17.0M-13.8M
Cash from investing63.4M-120.5M-26.0M-6.30M-1.72M-284.0K
Cash from financing9.00K162.2M24.4M-1.26M152.8M37.4M
Share buybacks0-4.18M-12.0K-5.00K
Change in cash-13.3M-13.3M-49.0M-58.4M135.7M23.6M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
8-K · Current reportNov 17, 2026Management or board changeSEC
8-K/A · Current report, amendedNov 9, 2026Current reportSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 3, 2026Insider tradeSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
8-K · Current reportOct 27, 2026ResultsSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
144 · Notice of proposed saleOct 6, 2026Other filingsSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
S-8 · Registration statement for employee plansSep 11, 2026Offer documentSEC
8-K · Current reportSep 11, 2026Management or board changeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipSep 4, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
144 · Notice of proposed saleAug 27, 2026Other filingsSEC
4 · Change in ownershipAug 19, 2026Insider tradeSEC
144 · Notice of proposed saleAug 18, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 10, 2026Big-stake noticeSEC
S-3 · Registration statementAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
ARS · Annual report to shareholdersAug 3, 2026Annual reportSEC
DEF 14A · Proxy statementAug 3, 2026Meeting noticeSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 23, 2026Big-stake noticeSEC
4 · Change in ownershipJul 23, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 23, 2026Insider tradeSEC
8-K · Current reportJul 22, 2026Current reportSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 15, 2026Big-stake noticeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 28, 2026Big-stake noticeSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Management or board changeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 18, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
8-K · Current reportMay 8, 2026Current reportSEC
424B5 · ProspectusMay 8, 2026Offer documentSEC
FWP · Free writing prospectusMay 8, 2026Offer documentSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
8-K · Current reportMay 8, 2026ResultsSEC
10-K/A · Annual report, amendedApr 30, 2026Annual reportSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 10, 2026Offer documentSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
3 · Initial statement of ownershipFeb 24, 2026Insider tradeSEC
8-K · Current reportFeb 24, 2026Management or board changeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 19, 2026Insider tradeSEC
8-K · Current reportFeb 19, 2026Management or board changeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
144 · Notice of proposed saleDec 15, 2025Other filingsSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
8-K · Current reportDec 12, 2025Management or board changeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
144 · Notice of proposed saleNov 17, 2025Other filingsSEC
8-K · Current reportNov 12, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
4 · Change in ownershipOct 17, 2025Insider tradeSEC
144 · Notice of proposed saleOct 17, 2025Other filingsSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 15, 2025Other filingsSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 11, 2025Other filingsSEC
S-3 · Registration statementAug 6, 2025Offer documentSEC
S-8 · Registration statement for employee plansAug 6, 2025Offer documentSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
4 · Change in ownershipJun 26, 2025Insider tradeSEC
8-K · Current reportJun 25, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
4 · Change in ownershipApr 25, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 25, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 23, 2025Big-stake noticeSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
8-K · Current reportMar 24, 2025ResultsSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipJan 29, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2025Insider tradeSEC
8-K · Current reportJan 29, 2025Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2024Insider tradeSEC
8-K · Current reportOct 22, 2024Management or board changeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedSep 3, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 29, 2024Quarterly reportSEC
8-K · Current reportAug 29, 2024ResultsSEC
SC 13G · Big-stake noticeAug 1, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeAug 1, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeAug 1, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJul 29, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeJul 29, 2024Big-stake noticeSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
SEC STAFF LETTERJul 23, 2024Other filingsSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
4 · Change in ownershipJul 22, 2024Insider tradeSEC
S-8 · Registration statement for employee plansJul 22, 2024Offer documentSEC
8-K · Current reportJul 22, 2024Current reportSEC
424B4 · ProspectusJul 19, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 19, 2024Other filingsSEC
3 · Initial statement of ownershipJul 18, 2024Insider tradeSEC

This page holds 200 of 240 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Artiva Biotherapeutics, Inc.’s releases · as of Oct 30, 2026

Common shares
49,432,351
Fully diluted
49,432,351

Fully diluted

LineSharesAs of
Common shares49,432,351Oct 30, 2026

Share count over time

CountShares
Oct 30, 202649,432,351

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.18.5M37.4%US$132MSep 30, 2026
Viking Global Investors LP2.6M5.3%US$18.5MSep 30, 2026
Blackstone Inc.2.4M4.9%US$17.1MSep 30, 2026
5AM Venture Management, LLC2.35M4.8%US$16.8MSep 30, 2026
Venrock Adviser, LLC2.04M4.1%US$14.6MSep 30, 2026
Franklin Templeton2.04M4.1%US$8.61MSep 30, 2026
BlackRock1.51M3.1%US$10.8MSep 30, 2026
Caligan Partners LP1.48M3.0%US$10.5MSep 30, 2026
Vanguard1.36M2.8%US$9.68MSep 30, 2026
Samsara Biocapital, LLC955K1.9%US$6.8MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Propel Bio Management, LLC696K1.4%US$4.96MSep 30, 2026
Geode Capital532K1.1%US$3.79MSep 30, 2026
Blue Owl Capital Holdings LP530K1.1%US$3.77MSep 30, 2026
State Street340K0.69%US$2.42MSep 30, 2026
Nantahala Capital Management, LLC300K0.61%US$2.14MSep 30, 2026
Revelation Capital Management, LLC299K0.61%US$2.13MSep 30, 2026
Alyeska Investment Group, L.P.274K0.55%US$1.95MSep 30, 2026
Boothbay Fund Management, LLC268K0.54%US$1.91MSep 30, 2026
Acuta Capital Partners, LLC260K0.53%US$1.85MSep 30, 2026
Acadian Asset Management LLC217K0.44%US$1.54MSep 30, 2026
KVP Capital Advisors, LP200K0.40%US$1.42MSep 30, 2026
Wellington194K0.39%US$1.38MSep 30, 2026
Northern Trust154K0.31%US$1.1MSep 30, 2026
Goldman Sachs151K0.31%US$1.08MSep 30, 2026
UBS103K0.21%US$737KSep 30, 2026
Simplify Asset Management Inc.101K0.21%US$722KSep 30, 2026
Prudential Financial Inc97,5050.20%US$694KSep 30, 2026
ExodusPoint Capital Management, LP95,5510.19%US$680KSep 30, 2026
ADAR1 Capital Management, LLC86,8050.18%US$618KSep 30, 2026
Bridgeway Capital Management, LLC84,4200.17%US$601KSep 30, 2026
Squarepoint Ops LLC74,6810.15%US$532KSep 30, 2026
Renaissance Technologies74,0780.15%US$527KSep 30, 2026
Two Sigma68,4540.14%US$487KSep 30, 2026
Schwab47,3920.10%US$337KSep 30, 2026
Bank of America47,2780.10%US$337KSep 30, 2026
Dimensional44,8150.09%US$319KSep 30, 2026
Millennium44,4610.09%US$317KSep 30, 2026
BNY41,9760.08%US$299KSep 30, 2026
Morgan Stanley40,5830.08%US$289KSep 30, 2026
Empowered Funds, LLC34,4200.07%US$245KSep 30, 2026
Atom Investors LP34,4200.07%US$245KSep 30, 2026
WINTON GROUP Ltd29,8040.06%US$212KSep 30, 2026
Y-Intercept (Hong Kong) Ltd29,6330.06%US$211KSep 30, 2026
Fox Run Management, L.L.C.28,0220.06%US$200KSep 30, 2026
Spark Investment Management LLC26,0000.05%US$185KSep 30, 2026
Nuveen25,8040.05%US$184KSep 30, 2026
Velan Capital Investment Management LP25,0000.05%US$178KSep 30, 2026
Sanctuary Advisors, LLC21,6320.04%US$154KSep 30, 2026
Bailard, Inc.20,7000.04%US$147KSep 30, 2026
Citadel16,3970.03%US$117KSep 30, 2026

This page holds 50 of 94 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund700K1.4%US$6.79MJun 30, 2026
Franklin Biotechnology Discovery Fund542K1.1%US$5.48MJul 31, 2026
Franklin Small Cap Growth Fund456K0.92%US$4.61MJul 31, 2026
Vanguard Extended Market Index Fund269K0.54%US$2.61MJun 30, 2026
iShares Russell 2000 ETF141K0.28%US$1.36MJun 30, 2026
Simplify Propel Opportunities ETF101K0.21%US$983KJun 30, 2026
Fidelity Small Cap Index Fund51,5570.10%US$521KJul 31, 2026
Ultra-Small Company Fund50,0000.10%US$485KJun 30, 2026
Ultra-Small Company Market Fund35,0000.07%US$340KJun 30, 2026
Fidelity Extended Market Index Fund30,8950.06%US$245KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
U.S. Micro Cap Portfolio27,4260.06%US$277KJul 31, 2026
Blackstone Alternative Multi-Strategy Fund23,0150.05%US$223KJun 30, 2026
iShares Russell 2000 Value ETF20,8250.04%US$202KJun 30, 2026
Nationwide Bailard Small Cap Value Fund20,7000.04%US$209KJul 31, 2026
Fidelity Nasdaq Composite Index Fund16,2580.03%US$129KMay 31, 2026
iShares Micro-Cap ETF15,7840.03%US$153KJun 30, 2026
Fidelity Total Market Index Fund15,6430.03%US$124KMay 31, 2026
Master Small Cap Index Series12,5700.03%US$122KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund11,8910.02%US$115KJun 30, 2026
Schwab Small-Cap Index Fund11,5150.02%US$116KJul 31, 2026
Fidelity Series Total Market Index Fund9,1810.02%US$72,805May 31, 2026
Vanguard Institutional Total Stock Market Index Fund8,7820.02%US$85,185Jun 30, 2026
EQ/AB Small Cap Growth Portfolio6,9900.01%US$67,803Jun 30, 2026
EQ/Small Company Index Portfolio6,9900.01%US$67,803Jun 30, 2026
EQ/2000 Managed Volatility Portfolio6,8980.01%US$66,911Jun 30, 2026
Nuveen Small Cap Blend Index Fund6,3420.01%US$64,054Jul 31, 2026
Dimensional U.S. Small Cap ETF5,8630.01%US$59,216Jul 31, 2026
Fidelity Small Cap Value Index Fund4,858<0.01%US$47,123Jun 30, 2026
Vanguard Balanced Index Fund3,985<0.01%US$38,655Jun 30, 2026
U.S. Social Core Equity 2 Portfolio3,040<0.01%US$30,704Jul 31, 2026
Dimensional US Core Equity 1 ETF3,029<0.01%US$30,593Jul 31, 2026
Small-Cap Index Portfolio2,737<0.01%US$26,549Jun 30, 2026
U.S. Small Cap Portfolio2,634<0.01%US$26,603Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio2,400<0.01%US$23,280Jun 30, 2026
Global X Russell 2000 ETF2,230<0.01%US$22,523Jul 31, 2026
Victory Extended Market Index Fund1,787<0.01%US$18,049Jul 31, 2026
Small Cap Index Fund1,739<0.01%US$16,868Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio1,410<0.01%US$13,677Jun 30, 2026
NVIT Small Cap Index Fund1,405<0.01%US$13,629Jun 30, 2026
BlackRock Small Cap Index V.I. Fund1,284<0.01%US$12,455Jun 30, 2026
Fidelity Small Cap Growth Index Fund1,201<0.01%US$11,650Jun 30, 2026
1290 VT Micro Cap Portfolio1,064<0.01%US$10,321Jun 30, 2026
Nationwide Small Cap Index Fund843<0.01%US$8,514Jul 31, 2026
SA Small Cap Index Portfolio745<0.01%US$7,525Jul 31, 2026
1290 VT Small Cap Value Portfolio728<0.01%US$7,062Jun 30, 2026
DWS Small Cap Index VIP717<0.01%US$6,955Jun 30, 2026
T. Rowe Price Small-Cap Index Fund706<0.01%US$6,848Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio557<0.01%US$5,403Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio421<0.01%US$4,084Jun 30, 2026
Total Stock Market Index Trust418<0.01%US$4,055Jun 30, 2026

This page holds 50 of 62 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Aslan Fred
Director, Officer: Chief Executive Officer
Sale119,771USD 3.91US$469KNov 17, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale4,037USD 3.91US$15,792Nov 17, 2026
Bush Jennifer
Officer: COO, CLO, Compliance Officer
Sale19,217USD 3.91US$75,175Nov 17, 2026
Horan Christopher
Officer: Chief Tech Operations Officer
Sale20,546USD 3.91US$80,374Nov 17, 2026
Miralles Gines Diego
Officer: President & Head of R&D
Sale1,043USD 3.91US$4,080Nov 17, 2026
Aslan Fred
Director, Officer: Chief Executive Officer
Sale62,178USD 4.18US$260KNov 2, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale1,110USD 4.18US$4,641Nov 2, 2026
Bush Jennifer
Officer: COO, CLO, Compliance Officer
Sale8,439USD 4.18US$35,284Nov 2, 2026
Horan Christopher
Officer: Chief Tech Operations Officer
Sale10,423USD 4.18US$43,580Nov 2, 2026
Aslan Fred
Director, Officer: Chief Executive Officer
Sale23,463USD 7.20US$169KOct 6, 2026
All 48 trades
TradeTradeSharesPriceValueDate
Aslan Fred
Director, Officer: Chief Executive Officer
Sale61,696USD 6.84US$422KOct 5, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale1,099USD 6.84US$7,514Oct 5, 2026
Bush Jennifer
Officer: COO, CLO, Compliance Officer
Sale8,370USD 6.84US$57,227Oct 5, 2026
Horan Christopher
Officer: Chief Tech Operations Officer
Sale10,340USD 6.84US$70,697Oct 5, 2026
Aslan Fred
Director, Officer: Chief Executive Officer
Sale23,429USD 10.92US$256KSep 8, 2026
Aslan Fred
Director, Officer: Chief Executive Officer
Sale61,888USD 11.16US$691KSep 3, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale1,100USD 11.16US$12,276Sep 3, 2026
Bush Jennifer
Officer: COO, CLO, Compliance Officer
Sale8,391USD 11.16US$93,644Sep 3, 2026
Horan Christopher
Officer: Chief Tech Operations Officer
Sale10,366USD 11.16US$116KSep 3, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale8,222USD 12.01US$98,746Aug 27, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale429USD 12.00US$5,148Aug 18, 2026
RA Capital Healthcare Fund LP
Director, 10% owner
Buy24,944USD 9.93US$248KJul 31, 2026
RA Capital Healthcare Fund LP
Director, 10% owner
Buy20,824USD 9.99US$208KJul 29, 2026
RA Capital Nexus Fund III, L.P.
Director
Buy41,319USD 9.99US$413KJul 24, 2026
Kolchinsky Peter
Director, 10% owner
Buy59,880USD 9.96US$596KJul 23, 2026
Kolchinsky Peter
Director, 10% owner
Buy84,124USD 9.93US$835KJul 22, 2026
Kolchinsky Peter
Director, 10% owner
Buy120,582USD 9.55US$1.15MJul 21, 2026
RA Capital Healthcare Fund LP
Director, 10% owner
Buy7,882USD 8.95US$70,544Jul 17, 2026
RA Capital Healthcare Fund LP
Director, 10% owner
Buy152,472USD 8.93US$1.36MJul 16, 2026
RA Capital Nexus Fund, L.P.
Director
Buy6,522USD 8.94US$58,307Jul 13, 2026
Shah Rajeev M.
Director, 10% owner
Buy6,552USD 8.94US$58,575Jul 13, 2026
Shah Rajeev M.
Director, 10% owner
Buy15,102USD 8.97US$135KJul 10, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy1,876USD 8.98US$16,846Jun 26, 2026
Ra Capital Management, L.P.
Director, 10% owner
Buy31,000USD 8.88US$275KJun 25, 2026
Kolchinsky Peter
Director, 10% owner
Buy124,893USD 8.89US$1.11MJun 16, 2026
Kolchinsky Peter
Director, 10% owner
Buy15,414USD 8.99US$139KJun 15, 2026
Kolchinsky Peter
Director, 10% owner
Buy391,019USD 8.57US$3.35MJun 12, 2026
RA Capital Nexus Fund, L.P.
Director
Buy548,580USD 7.91US$4.34MJun 11, 2026
RA Capital Nexus Fund, L.P.
Director
Buy103USD 7.00US$721Jun 10, 2026
RA Capital Nexus Fund, L.P.
Director
Buy479,039USD 6.91US$3.31MJun 9, 2026
Aslan Fred
Director, Officer: Chief Executive Officer
Sale27,116USD 9.01US$244KMay 19, 2026
Banerjee Subhashis
Officer: Chief Medical Officer
Sale7,037USD 9.01US$63,403May 19, 2026
Bush Jennifer
Officer: COO, CLO, Compliance Officer
Sale8,790USD 9.01US$79,198May 19, 2026
Horan Christopher
Officer: Chief Tech Operations Officer
Sale7,002USD 9.01US$63,088May 19, 2026
Raymon Heather
Officer: SVP, Research and Development
Sale3,095USD 9.01US$27,886May 19, 2026
GC Corp
10% owner
Buy1,085,069USD 11.52US$12.5MMay 11, 2026
GC Corp
10% owner
Buy347,222USD 11.52US$4MMay 11, 2026
RA Capital Nexus Fund III, L.P.
Director
Buy6,510,416USD 11.52US$75MMay 11, 2026

Big stakes

StakeStakeSharesDateFiling
Ra Capital Management, L.P.37.90%18.4MJul 22, 2026Schedule 13D
GC Corp12.30%6MMay 11, 2026Schedule 13D
Viking Global Investors LP5.40%2.6MMay 11, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Since at least Jul 18, 2024
Daniel Baker
Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Cue Biopharma, Inc. (CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024)
Director · Since at least Jan 28, 2025
Elizabeth L. Hougen
Other companies: Ionis Pharmaceuticals, Inc. (Executive Vice President, Chief Financial Officer · Since at least Jan 1, 2013); Akcea Therapeutics Inc (Chief Financial Officer · Jul 13, 2017 – Jul 13, 2017 · Past)
Director · Since at least Jul 18, 2024
Peter Kolchinsky
Other companies: Vor Biopharma Inc. (Director · Since at least Apr 2, 2026); ARS Pharmaceuticals, Inc. (Director · Since at least Sep 30, 2025)
Director · Since at least Jun 12, 2026
Alison Moore
Other companies: Codexis, Inc. (President and CEO, Director · Since at least Oct 13, 2025)
Director · Since at least Jun 24, 2025
Diego Miralles
Other companies: Contineum Therapeutics, Inc. (President and Head of Research and Development, Artiva Biotherapeutics, Inc. · Since at least Mar 17, 2025)
Director · Since at least Aug 6, 2026
Gines Diego Miralles
Other companies: Contineum Therapeutics, Inc. (Director · Since at least Jun 26, 2025)
President & Head of R&D · Since at least Jun 24, 2025
Thad Huston
Other companies: LivaNova PLC (Chief Financial Officer · May 20, 2017 – May 23, 2020 · Past)
Chief Financial Officer and Award of Inducement Grant · Since at least Feb 18, 2026
Adria CarboVP, Business Development · Since at least Nov 5, 2026
Benjamin DeweesSVP, Regulatory Affairs · Since at least Nov 5, 2026
All 25 people
PersonSeat
Christopher HoranChief Technical Operations Officer · Since at least Jul 18, 2024
Cliff WallaceVP, Quality · Since at least Nov 4, 2026
David MoriartySVP, Clinical Operations · Since at least Nov 5, 2026
Elaine SorgDirector · Since at least Feb 19, 2026
Feng XuSVP, Biometrics · Since at least Nov 5, 2026
Fred AslanChief Executive Officer · Since at least Oct 27, 2026
Heather RaymonSVP, Research & Early Development · Since at least Jul 18, 2024
Ilias AlevizosVP, Clinical Development · Since at least Nov 5, 2026
Jennifer BushCOO, CLO, Compliance Officer · Since at least Jul 18, 2024
John O’NeilVP, Finance · Since at least Nov 5, 2026
Larry KovalickVP, Medical Affairs · Since at least Nov 4, 2026
Nicholas VeomettVP, Corporate Development · Since at least Nov 5, 2026
Sara MillsVice President, AlloNK® Program Leader · Since at least Nov 5, 2026
Subhashis BanerjeeChief Medical Officer · Since at least Apr 8, 2025
Yong-Jun HuhDirector · Jul 18, 2024 – Jul 22, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Artiva Biotherapeutics, Inc.